1. Market Research
  2. > All Companies
  3. > Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile

Summary

Rosetta Genomics, Ltd. (RGL) is a biotechnology company that discovers, develops and commercializes next generation diagnostic tests for personalized medicine. The company provides testing services such as rosetta cancer origin test, resetta lung cancer test, rosetta kidney cancer test and rosetta mesothelioma test. It is developing tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company has presence in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2010 to YTD 2016 7
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2010 to YTD 2016 9
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Rosetta Genomics, Ltd., Medical Equipment, Deal Details 12
Partnerships 12
Rosetta Genomics Terminates Licensing Agreement With Avatao Biotech 12
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 13
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 14
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 15
Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16
Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21
Rosetta Genomics Expands Distribution Agreement With Genekor 22
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 25
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 26
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 27
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 29
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 30
Rosetta Genomics Enters Into Distribution Agreement With Genekor 31
Rosetta Genomics Terminates Its Licensing Agreement With Prometheus Labs 32
Equity Offering 33
Rosetta Genomics to Raise USD8 Million in Private Placement of Units 33
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 35
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 36
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 38
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 40
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 41
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 42
Rosetta Genomics Completes Private Placement For US$2.7 Million 44
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 46
Rosetta Genomics Completes Private Placement For US$2.5 Million 48
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 50
Debt Offering 52
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 52
Acquisition 53
Rosetta Genomics Acquires PersonalizeDx from Prelude 53
Rosetta Genomics, Ltd. - Key Competitors 54
Key Employees 55
Locations And Subsidiaries 56
Head Office 56
Other Locations and Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Mar 23, 2016: Rosetta Genomics Reports 2015 Full Year Financial Results 57
Dec 01, 2015: Rosetta Genomics Reports Third Quarter 2015 Financial Results 59
Oct 26, 2015: Rosetta Genomics Reports Financial Results for the First Half of 2015 61
Mar 16, 2015: Rosetta Genomics Reports 2014 Financial Results 63
Corporate Communications 65
Feb 29, 2016: Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development 65
Nov 04, 2015: Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer 66
Product News 67
May 12, 2015: Data on Rosetta Genomics' Novel Thyroid Nodule Classification Assay to be Presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress 67
Mar 26, 2015: Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test 68
Feb 26, 2015: Rosetta Genomics Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of Development 69
Jan 20, 2015: Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test Published in the Journal of Kidney Cancer 70
Other Significant Developments 71
Jun 16, 2015: Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Rosetta Genomics, Ltd., Medical Equipment, Key Facts, 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2010 to YTD 2016 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2010 to YTD 2016 7
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Rosetta Genomics, Ltd., Deals By Market, 2010 to YTD 2016 9
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Rosetta Genomics Terminates Licensing Agreement With Avatao Biotech 12
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 13
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 14
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 15
Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16
Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21
Rosetta Genomics Expands Distribution Agreement With Genekor 22
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 25
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 26
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 27
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 29
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 30
Rosetta Genomics Enters Into Distribution Agreement With Genekor 31
Rosetta Genomics Terminates Its Licensing Agreement With Prometheus Labs 32
Rosetta Genomics to Raise USD8 Million in Private Placement of Units 33
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 35
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 36
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 38
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 40
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 41
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 42
Rosetta Genomics Completes Private Placement For US$2.7 Million 44
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 46
Rosetta Genomics Completes Private Placement For US$2.5 Million 48
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 50
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 52
Rosetta Genomics Acquires PersonalizeDx from Prelude 53
Rosetta Genomics, Ltd., Key Competitors 54
Rosetta Genomics, Ltd., Key Employees 55
Rosetta Genomics, Ltd., Other Locations 56
Rosetta Genomics, Ltd., Subsidiaries 56

List of Figures
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2010 to YTD 2016 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2010 to YTD 2016 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2010 to YTD 2016 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2010 to YTD 2016 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2010 to YTD 2016 7
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Rosetta Genomics, Ltd., Medical Equipment, Deals by Market, 2010 to YTD 2016 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2016 Update

Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • March 2016
  • by Global Data

Summary Genomic Health, Inc. (Genomic Health) is a provider of genomic-based clinical laboratory services for the treatment of cancer. The company’s commercial product portfolio comprises Onco type DX ...

Genomic Vision (GV) - Product Pipeline Analysis, 2016 Update

Genomic Vision (GV) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • April 2016
  • by Global Data

Summary Genomic Vision (Genomic) is a molecular diagnostics company that develops and commercializes diagnostic tests for genetic diseases and cancers. The company’s portfolio comprises tests for breast ...

Rosetta Genomics, Ltd. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Rosetta Genomics, Ltd. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • March 2016
  • by MarketLine

Project Synopsis: Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.